表紙
市場調査レポート

世界の薬物乱用検査市場の将来動向

Global Drug Abuse Testing Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 317280
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
世界の薬物乱用検査市場の将来動向 Global Drug Abuse Testing Market 2014-2018
出版日: 2014年10月22日 ページ情報: 英文 75 Pages
概要

薬物とは、疾患の診断・治療・予防を目的とした化学物質です。そのため、薬物を医薬品として適切に利用すれば、患者に正の効果が働きます。しかし、薬物を治療以外の目的で使った場合には、健康上の深刻な問題が生じます。薬物乱用検査とは、ある人物が使用した薬剤(または複数の薬剤の組み合わせ)を検知するために生体試料を分析する手法です。検査に用いられる生体試料には、唾液や尿、血液、毛髪、呼吸、汗などがあります。主な検査手法には、免疫検定法とクロマトグラフィー(色層分析)の2種類があります。薬物乱用検査は、疾患診断や刑事事件捜査、スポーツ選手のドーピング検査など幅広い用途で実施されています。全世界の薬物乱用検査市場の2013〜2018年の年平均成長率(CAGR)は4.71%に達する見通しです。

当レポートでは、全世界の薬物乱用検査市場について分析し、疾患・検査方法の概要や基本的市場構造、市場規模の動向(今後5年間の予測値)、検査手法別・地域別の詳細動向、市場の促進・抑制要因とその影響力、主要企業のプロファイル、今後の市場機会などを調査・考察しております

第1章 エグゼクティブ・サマリー

第2章 略語集

第3章 分析範囲

  • 市場概要
  • 主な製品・サービス

第4章 市場分析の手法

  • 市場分析のプロセス
  • 分析手法

第5章 イントロダクション

第6章 概要

  • 疫学
  • 一般的な薬物乱用
  • 薬物乱用による傷害

第7章 市場環境

  • 市場概況
  • 市場規模とその予測
  • ファイブフォース分析

第8章 手法別の市場分析

第9章 地域別の分析

  • 南北アメリカ市場
  • 欧州・中東・アフリカ(EMEA)地域市場
  • アジア太平洋地域市場

第10章 購入基準

第11章 市場の成長促進要因

第12章 促進要因とその影響力

第13章 市場の課題

第14章 促進要因・課題の影響力

第15章 市場の傾向

第16章 市場動向とその影響

第17章 ベンダー環境

  • 競争シナリオ
    • 近年の主な動向
    • 企業合併・買収(M&A)
  • 市場シェア分析
  • その他の著名なベンダー

第18章 主要ベンダーの分析

  • Bio-Rad
    • 主要データ
    • 事業概要
    • 事業分類
    • 事業戦略
    • 部門別の市場収益額(最新値)
    • 部門別の市場収益額(前年度との比較)
    • 地域別の市場収益額
    • 近年の動向
    • SWOT分析
  • Danaher
  • F. Hoffmann-La Roche
  • Siemens
  • Thermo Fisher Scientific

第19章 その他の関連分析

図表一覧

目次
Product Code: IRTNTR4393

About Drug Abuse Testing

Drugs are chemical substances, which are generally used in the diagnosis, treatment, and prevention of diseases. Drugs when used as medicines have positive effects on patients; however, some people use drugs for non-medical purposes, which leads to serious health problems. Drug abuse testing is a technical analysis of biological specimen to determine the drugs or combination of drugs consumed by a person. The biological specimens used for the test are saliva, urine, blood, hair, breath, and sweat. The two main technologies used to test drug abuse are immunoassay and chromatography. Drug abuse testing is widely used in diagnostics, criminal cases, and to screen sports athletes.

TechNavio's analysts forecast the Global Drug Abuse Testing market to grow at a CAGR of 4.71 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Drug Abuse Testing market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from sales of drug abuse testing solutions, which includes drug abuse testing kits and systems. The technologies primarily considered in the report are immunoassay and chromatography.

TechNavio's report, the Global Drug Abuse Testing Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC and EMEA regions; it also covers the Global Drug Abuse Testing market landscape and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bio-Rad Laboratories
  • Danaher
  • F. Hoffmann-La Roche
  • Siemens
  • Thermo Fisher Scientific

Other Prominent Vendors

  • Abbott Laboratories
  • Agilent Technologies
  • Alere
  • Biomedical Diagnostics
  • Branan Medical
  • OraSure Technologies
  • PerkinElmer
  • Psychemedics
  • Quest Diagnostic
  • Randox Laboratories
  • Sigma-Aldrich
  • Sonic Healthcare
  • Waters

Market Driver

  • Rise in Consumption of Illicit Drugs
  • For a full, detailed list, view our report

Market Challenge

  • Inability to Detect Low-dose Designer Drugs
  • For a full, detailed list, view our report

Market Trend

  • Increase in Number of Collaborations and M&A
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2018 and what will the growth rate be
  • What are the key market trends
  • What is driving this market
  • What are the challenges to market growth
  • Who are the key vendors in this market space
  • What are the market opportunities and threats faced by the key vendors
  • What are the strengths and weaknesses of the key vendors

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Overview

  • 06.1. Epidemiology
  • 06.2. Commonly Abused Drugs:
  • 06.3. Harm Caused by Drugs Abuse

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. Five Forces Analysis

08. Market Segmentation by Technique

09. Geographical Segmentation

  • 09.1. Drugs Abuse Testing Market in Americas
    • 09.1.1. Market Size and Forecast
  • 09.2. Drugs Abuse Testing Market in EMEA Region
    • 09.2.1. Market Size and Forecast
  • 09.3. Drugs Abuse Testing Market in APAC Region
    • 09.3.1. Market Size and Forecast

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Vendor Analysis 2013
  • 17.3. Other Prominent Vendors

18. Key Vendor Analysis

  • 18.1. Bio-Rad
    • 18.1.1. Key Facts
    • 18.1.2. Business Overview
    • 18.1.3. Business Segmentation
    • 18.1.4. Business Strategy
    • 18.1.5. Business Segmentation by Revenue
    • 18.1.6. Business Segmentation by Revenue 2011KKKKK and 2012
    • 18.1.7. Geographical Segmentation by Revenue 2012
    • 18.1.8. Key Developments
    • 18.1.9. SWOT Analysis
  • 18.2. Danaher
    • 18.2.1. Key Facts
    • 18.2.2. Business Overview
    • 18.2.3. Business Segmentation
    • 18.2.4. Revenue by Business Segmentation
    • 18.2.5. Revenue Comparison 2012KKKKK and 2013
    • 18.2.6. Segmentation by Geography
    • 18.2.7. Business Strategy
    • 18.2.8. Key Information
    • 18.2.9. SWOT Analysis
  • 18.3. F. Hoffmann-La Roche
    • 18.3.1. Key Facts
    • 18.3.2. Business Overview
    • 18.3.3. Business Segmentation by Revenue 2013
    • 18.3.4. Business Segmentation by Revenue 2012KKKKK and 2013
    • 18.3.5. Geographical Segmentation by Revenue 2013
    • 18.3.6. Business Strategy
    • 18.3.7. Recent Developments
    • 18.3.8. SWOT Analysis
  • 18.4. Siemens
    • 18.4.1. Key Facts
    • 18.4.2. Business Overview
    • 18.4.3. Business Segmentation 2013
    • 18.4.4. Revenue by Business Segmentation 2013
    • 18.4.5. Revenue Comparison by Business Segmentation 2012KKKKK and 2013
    • 18.4.6. Geographical Segmentation by Revenue 2013
    • 18.4.7. Business Strategy
    • 18.4.8. Recent Developments
    • 18.4.9. SWOT Analysis
  • 18.5. Thermo Fisher Scientific
    • 18.5.1. Key Facts
    • 18.5.2. Business Overview
    • 18.5.3. Business Segmentation
    • 18.5.4. Business Segmentation by Revenue
    • 18.5.5. Product Segmentation by Revenue
    • 18.5.6. Geographical Segmentation by Revenue 2013
    • 18.5.7. Business Strategy
    • 18.5.8. Key Information
    • 18.5.9. SWOT Analysis

19. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Harm Caused by Drugs Abuse
  • Exhibit 3: Global Drugs Abuse Testing Market 2013-2018 (US$ million)
  • Exhibit 4: Global Drugs Abuse Testing Market Segmentation by Technology
  • Exhibit 5: Global Drugs Abuse Testing Market Segmentation by Geography 2013
  • Exhibit 6: Drugs Abuse Testing Market in Americas 2013-2018 (US$ million)
  • Exhibit 7: Drugs Abuse Testing Market in EMEA Region 2013-2018 (US$ million)
  • Exhibit 8: Drugs Abuse Testing Market in APAC Region 2013-2018 (US$ million)
  • Exhibit 9: Bio-Rad: Business Segmentation
  • Exhibit 10: Bio-Rad: Business Segmentation by Revenue 2012
  • Exhibit 11: Bio-Rad: Business Segmentation by Revenue 2011 and 2012 (US$ million)
  • Exhibit 12: Bio-Rad: Geographical Segmentation by Revenue 2012
  • Exhibit 13: Danaher: Business Segmentation
  • Exhibit 14: Danaher: Business Segmentation 2013
  • Exhibit 15: Danaher: Revenue by Business Segmentation 2012 and 2013 (US$ million)
  • Exhibit 16: Danaher: Revenue by Geographical Segmentation 2013
  • Exhibit 17: F. Hoffmann-La Roche: Business Segmentation by Revenue 2013
  • Exhibit 18: F. Hoffmann-La Roche: Business Segmentation by Revenue 2012 and 2013 (US$ million)
  • Exhibit 19: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Pharmaceuticals)
  • Exhibit 20: F. Hoffmann-La Roche: Geographical Segmentation by Revenue 2013 (Diagnostics)
  • Exhibit 21: Siemens: Business Segmentation 2013
  • Exhibit 22: Siemens: Revenue by Business Segmentation 2013
  • Exhibit 23: Siemens: Revenue by Business Segmentation 2012 and 2013 (US$ billion)
  • Exhibit 24: Siemens: Geographical Segmentation by Revenue 2013
  • Exhibit 25: Thermo Fisher: Business Segmentation
  • Exhibit 26: Thermo Fisher: Business Segmentation by Revenue 2013
  • Exhibit 27: Thermo Fisher: Product Segmentation by Revenue 2013
  • Exhibit 28: Thermo Fisher: Geographical Segmentation by Revenue 2013
Back to Top